Stock KZR KEZAR LIFE SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Kezar Life Sciences, Inc.

Equities

KZR

US49372L1008

Market Closed - Nasdaq
Other stock markets
 21:00:00 10/05/2024 BST 		5-day change 1st Jan Change
0.7727 USD -5.42% Intraday chart for Kezar Life Sciences, Inc. -9.88% -18.44%
05-09 Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
03-14 Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kezar Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
BU
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BU
Kezar Life Sciences Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Update
BU
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BU
Kezar Life Sciences to Participate in the TD Cowen 44th Annual Health Care Conference
BU
Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis
BU
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kezar Life Sciences, Inc. (NASDAQ: KZR)
PR
Kezar Life Sciences to Present at the 6th Annual Evercore ISI HealthCONx Conference
BU
Kezar Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
BU
Autoimmune Hepatitis Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BU
KEZAR ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(4)
AQ
Myositis Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)
AQ
Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BU
Kezar Life Sciences Announces Strategic Restructuring to Prioritize Clinical-Stage Assets and Extend Financial Runway and Appoints Christopher Kirk, Ph.D. as Chief Executive Officer
BU
Everest Medicines Enters into Collaboration and License Agreement with Kezar Life Sciences to Develop and Commercialize Zetomipzomib in Greater China and other Asian Markets
AQ
Kezar Life Sciences and Everest Medicines Enter into an Agreement to Develop and Commercialize Zetomipzomib for Lupus Nephritis and other Potential Indications in Greater China, South Korea and Southeast Asia
BU
Kezar Life Sciences to Participate in Three Upcoming Investor Conferences
BU
Kezar Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KZR Stock
  4. News Kezar Life Sciences, Inc.
  5. Press Releases